CAS 802539-81-7 – N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazi…

CAS No.

802539-81-7

MDL No.

MFCD17169990

C₂₅H₃₂N₈O

460.60

InChI Key

RXZMYLDMFYNEIM-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

On Request

Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	802539-81-7
Product Name	N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Biological Targets

CDK1·CDK2·CDK4·NTRK1

Associated Conditions

Thymic Carcinoma·Thymoma·neoplasm·hepatocellular carcinoma

* The information provided here is compiled from public sources and is for reference only.

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Documentation

Similar Products

Onvansertib

NMS-P715

LNK4-S

Vinorelbine